Mackenzie Financial
KROS icon

Mackenzie Financial’s Keros Therapeutics KROS Stock Holding History

Mackenzie Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.72M Buy
628,438
+475,988
+312% +$5.3M 0.01% 754
2026
Q1 		$1.68M Buy
152,450
+101,065
+197% +$1.56M ﹤0.01% 971
2025
Q4 		$1.04M Sell
51,385
-5,383
-9% -$94.4K ﹤0.01% 1041
2025
Q3 		$898K Buy
56,768
+2,891
+5% +$42.7K ﹤0.01% 1095
2025
Q2 		$719K Buy
+53,877
New +$727K ﹤0.01% 1106

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Mackenzie Financial's KROS Position: Q2 2026 in Review

Mackenzie Financial increased its Keros Therapeutics (KROS) stake by 312% in Q2 2026, buying an estimated $5.3M and bringing the position to 628,438 shares worth $6.72M. The position accounts for 0.01% of the portfolio, ranked #754.

Mackenzie Financial first reported a position in KROS in Q2 2025 and has held it in 5 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Mackenzie Financial held 628,438 shares of Keros Therapeutics worth $6.72M as of Q2 2026.
  • Mackenzie Financial bought 475,988 Keros Therapeutics shares in Q2 2026, an estimated $5.3M.
  • Keros Therapeutics made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #754 holding.
  • Mackenzie Financial first reported a position in Keros Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.